Phase II trial of Abemaciclib in Unresectable or Metastatic Anaplastic Thyroid Cancer

We report our clinical trial with abemaciclib, an oral CDK4/6 inhibitor, in patients with incurable ATC after FDA-approved treatment options.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: S. Sheth, R. Lu, H. Zhu, E. Ugwu, F. Qin, H. Morton, M. Steffen, C. Miles, E. Winters, S. Lai, H. Kang, V. Khanna, S. Khan Tags: 249 Source Type: research